Clinical Trials Logo

Peyronie's Disease clinical trials

View clinical trials related to Peyronie's Disease.

Filter by:

NCT ID: NCT05873595 Recruiting - Peyronie's Disease Clinical Trials

Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease

CURVE-PD
Start date: June 20, 2023
Phase:
Study type: Observational [Patient Registry]

This is an observational study, meaning participants will not receive any investigational treatment as part of this study. Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of Peyronie's Disease (PD) to evaluate the management of PD.

NCT ID: NCT05855070 Not yet recruiting - Hyaluronic Acid Clinical Trials

Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease

Start date: May 20, 2023
Phase: N/A
Study type: Interventional

The aim of the present study is to investigate whether intralesional injections of Hyaluronic acid in the acute phase could reduce the progression of Peyronie's disease thanks to its interference with inflammatory and pro-fibrotic processes. Therefore, a prospective, longitudinal, double-blinded, randomized clinical study, has been designed to evaluate and compare the efficacy and safety of intralesional HA as compared with the use of verapamil injection in patients affected by Peyronie's disease.

NCT ID: NCT05147779 Recruiting - Clinical trials for Erectile Dysfunction

Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis

Start date: September 12, 2021
Phase: Phase 1
Study type: Interventional

This trial will study the safety and efficacy of intravenous and intracavernosal or interstitial delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Peyronie's disease, erectile dysfunction , and Interstitial Cystitis

NCT ID: NCT05108558 Recruiting - Peyronie's Disease Clinical Trials

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

Start date: September 20, 2021
Phase: Phase 4
Study type: Interventional

Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.

NCT ID: NCT04786106 Active, not recruiting - Peyronie's Disease Clinical Trials

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

iSCRIP
Start date: December 30, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare key clinical outcomes of collagenase clostridium histolyticum injections versus surgery for the management of Peyronie's Disease.

NCT ID: NCT03767452 Recruiting - Peyronie's Disease Clinical Trials

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

Start date: October 4, 2018
Phase: Phase 4
Study type: Interventional

Subjects who have had an incomplete response to previous Xiaflex® will receive up to 4 additional cycles of treatment.

NCT ID: NCT02395029 Completed - Peyronie's Disease Clinical Trials

Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD

PMD-MSC-PD-01
Start date: August 2013
Phase: Phase 1
Study type: Interventional

Prospective, open labeled, non-randomized, study to be conducted at a single center. Ten subjects will undergo an injection of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs) into the penis for the treatment of Peyronie's Disease. Follow up visits will be conducted at 6 weeks, 3 months, 6 months, and 12 months. Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on patient reported treatment satisfaction.

NCT ID: NCT02298829 Completed - Peyronie's Disease Clinical Trials

Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease

Start date: November 2014
Phase:
Study type: Observational

This a Phase 4 non-treatment, long-term follow-up study of subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc. After participation in one of the aforementioned studies, subjects will be followed yearly for up to 4 consecutive long-term follow-up visits with at least 6 months between consecutive visits

NCT ID: NCT02267460 Completed - Peyronie's Disease Clinical Trials

An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease

Start date: October 2014
Phase: Phase 3
Study type: Interventional

Enrollment will include approximately 30 AA4500 naïve subjects. Subjects will be divided by degree of penile curvature and then randomized in a 1:1 ratio to one of the following treatment groups: - AA4500 with investigator modeling - AA4500 without investigator modeling Each subject will receive 2 injections of AA4500, separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles. Approximately 14 days after the second injection of AA4500, each subject will visit the study site and the investigator will assess the subject and instruct the subject on appropriate use of the ErecAid® Esteem® Manual Vacuum Therapy System.

NCT ID: NCT02072018 Completed - Peyronie's Disease Clinical Trials

Peyronie's Disease Treatment Protocol

Start date: June 2013
Phase: Phase 1
Study type: Interventional

Treatment of Peyronie's disease remains difficult. The purpose of this study is to test the safety and efficacy of a new compound to treat this disease.